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Phlegmasia cerulea dolens is a rare but serious complication of deep venous thrombosis, which can lead to arterial
compromise, tissue ischemia, and gangrene. It typically presents in an elderly population often with coexistent
malignancy. There have been no reported cases in the ambulatory pediatric population. The authors report a case of a
5-year-old girl who presented with acute, extensive left lower extremity deep venous thrombosis resulting in phlegmasia
cerulea dolens. Pharmacologic and mechanical interventions as described in the adult population were utilized. This case
demonstrates that an aggressive, multimodal approach to phlegmasia cerulea dolens can be employed in the pediatric
population and result in successful limb salvage. (J Vasc Surg 2011;53:212-5.)Phlegmasia cerulea dolens (PCD) is an uncommon but
serious complication of deep venous thrombosis. Mortality
has been reported to be as high as 41% and ultimate
amputation may be necessary in 50% of survivors.1 Treat-
ment options include systemic anticoagulation, systemic
thrombolytic therapy, catheter-directed thrombolysis, me-
chanical thrombectomy, and surgical thrombectomy.2 The
appearance of PCD in the ambulatory pediatric population
has not been reported. Correspondingly, there have been
no reports of invasive treatment with thrombolysis and
pharmacomechanical thrombectomy in pediatric patients
with PCD. We report the case of PCD presenting in a
5-year-old girl without previously documented comorbidi-
ties. Aggressive intervention using a multimodal approach
was successfully implemented and avoided limb loss in this
young patient.
CASE REPORT
A 5-year-old girl presented to her pediatrician with a 4-month
history of hematochezia, progressive weakness, and a 10-pound
weight loss. Upon admission, she was transfused for a microcytic
anemia with a hemoglobin of 7.2 mg/dL. Her stool culture and a
Meckel’s scan were negative. During the first few days, it was
difficult to keep up with her fluid losses, mostly in the form of
abnormal urine output. Her hemoglobinA1c was determined to be
elevated at 7.8%, and insulin treatment was instituted for newly
diagnosed diabetes. On the day of a scheduled elective colonos-
copy, she awoke with severe pain, swelling, and discoloration of the
left lower extremity. Vascular surgery was consulted.
At presentation, the patient was ill appearing, afebrile, and
without tachycardia. Her weight was 16.3 kg (22nd percentile for
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212age) and height 109 cm (55th percentile for age). Her examination
was significant for a cold, swollen, painful left lower extremity with
bluish discoloration consistent with PCD (Fig 1). The vascular
examination was significant for a palpable left femoral pulse with-
out distal pulses, and normal pulses in the right lower extremity.
Only weak venous Doppler signals were present in the left dorsalis
pedis and posterior tibial positions. A venous duplex ultrasound
showed extensive deep venous thrombosis extending from the left
external iliac vein to the left popliteal vein. There were noted to be
arterial waveforms in the tibial arteries. Systemic anticoagulation
with intravenous, unfractionated heparin was begun, and the pa-
tient’s leg was elevated. A hypercoagulable workup was initiated.
Given the severe compromise of the limb, catheter directed
thrombolysis (CDT) was immediately pursued. With the patient in
a prone position, the left popliteal vein was accessed under ultra-
sound guidance and a 5F vascular sheath placed. The initial
venogram showed the extensive left iliofemoral deep venous
thrombosis (Fig 2, A). A Spiroflex VG AngioJet catheter (Possis
Medical, Minneapolis, Minn) was inserted and the power pulse
technique used to infuse tissue plasminogen activator (10 mg
Alteplase [Genentech, South San Francisco, Calif]/50 mL normal
saline) across the iliofemoral veins. Transient hematuria and nose
bleeding were noted but resolved before the end of the case. After
waiting 30 minutes, the Spiroflex catheter was passed across the
thrombosed veins from bottom to top and back in AngioJet mode.
Follow-up venography demonstrated resolution of all throm-
bus and rapid antegrade venous flow but with a residual linear
defect near the origin of the left common iliac vein consistent with
May-Thurner syndrome (MTS). Balloon angioplasty of the left
common iliac vein was performed using a 10  40 mm balloon.
Completion venogram showed a persistent oblique linear filling
defect (Fig 2, B). Consideration was given to stenting; however,
given the patient’s young age and the uncertain long-term out-
comes of stents in this position, the decision was made not to stent.
The patient was continued on a heparin infusion at a rate of 20
units/kg via the popliteal venous sheath.
Clinically, the patient’s left leg edema markedly improved,
with diminution of the cyanosis and resolution of the pain by
postprocedure day one. Triphasic Doppler signals were present in
the left dorsalis pedis and posterior tibial positions. The sheath was
removed, and the patient was transitioned to therapeutic enoxapa-
rin (1.2 mg/kg/dose given twice a day). The patient underwent
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diabetes. The patient developed some mild recurrent edema and a
venous ultrasound obtained on postprocedure day 14 demon-
strated nonocclusive venous thrombosis involving the left femoral
and popliteal veins.
Given the magnitude of the recurrent clot, the patient was
returned to the interventional suite on postprocedure day 15 for a
repeat venogram. A left lower extremity and pelvic venogram was
performed as before by accessing the left popliteal vein and placing
a 5F vascular sheath. Nonocclusive thrombus was found extending
from the popliteal vein to the external iliac vein. This was retreated
with Spiroflex VG AngioJet in Angiojet mode in standard fashion.
A 5  40 mm angioplasty balloon was inflated in the left popliteal
Fig 1. Initial appearance of leg.
Fig 2. A, Venogram pretreatment. B, Venogram posttreatment.vein to break up clot resistant to AngioJet thrombolysis. Thepersistent linear defect at the origin of the left common iliac vein
was again seen, as well as interval development of iliac to caval
collaterals suggestive of the hemodynamic significance of the May-
Thurner physiology (Fig 3, A). A 12  30 mm Luminexx stent
(Bard Peripheral Vascular, Tempe, Ariz) was deployed across the
left common iliac vein stenosis and then postdilated to wide
patency (Fig 3, B). The patient was resumed on enoxaparin and
transitioned to coumadin. The patient’s leg symptoms improved
with minimal pain and resolution of the edema. A venous duplex
ultrasound prior to discharge demonstrated no evidence of deep
venous thrombosis throughout the left leg.
During her hospital course, the patient underwent colonos-
copy and was diagnosed with a nonspecific colitis. She was treated
with mesalamine (Asacol) for colitis and had resolution of hema-
tochezia. Hypercoagulable workup revealed homozygosity for the
methylene tetrahydrofolate reductase (MTHFR) gene mutation.
The remainder of the workup was negative including a normal
homocysteine level. The patient was seen 6 months after discharge
and was free of any symptoms of chronic venous insufficiency and
had a normal physical examination (Fig 4).
DISCUSSION
Phlegmasia cerulea dolens (PCD) is a rare but serious
complication of deep venous thrombosis. When the exten-
sive venous thromboses include that of collateral veins,
arterial compromise may develop and lead to gangrene.2
Increases in venous pressure and fluid sequestration can
lead to bullae formation and circulatory shock.3 The clinical
presentation of PCD includes the triad of swelling, cyano-
sis, and pain in the affected extremity, and the left leg is
Fig 3. A, Venogram prestent. B, Venogram poststent.affected three times more often than the right.4 While
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distal to proximal, cyanosis is a reversible stage where
aggressive management can be employed before gangrene
occurs. Moreover, the chronic effects of postthrombotic
syndrome can potentially be avoided with early thrombus
resolution.2
Risk factors for the development of deep venous
thrombosis include stasis, vascular wall injury, and hyper-
coagulable states. The patient in this report demonstrated
MTS, an acquired abnormality resulting from chronic com-
pression of the left common iliac vein by the right common
iliac artery, with resultant lower extremity outflow obstruc-
tion. The majority of patients with MTS are women in their
third to fifth decade of life.5 Only a few pediatric patients
with symptomatic MTS undergoing endovascular treat-
ment have been reported in the literature, including two
teenage girls on oral contraception and a 10-year-old boy
without known hypercoagulable risk factors.6,7 Our patient
had had no surgery or other interventions that may have
caused vascular wall injury. However, her dehydration and
relatively immobility during her hospitalization for newly
diagnosed brittle diabetes and chronic hematochezia likely
Fig 4. Appearance of leg in 6 months.contributed to a relative hypercoagulable state. Malignancyis a common association with primary venous thrombosis,
yet uncommon in the pediatric population.
Investigation for heritable hypercoagulable states is
important in patients with idiopathic deep vein thrombosis.
Prothrombin gene polymorphism, factor V Leiden poly-
morphism, protein C and S deficiency, and antiphospho-
lipid antibody syndrome are some of the more commonly
recognized genetic risks for deep vein thrombosis. Hyper-
coagulable workup of our patient revealed homozygosity
for methylene tetrahydrofolate reductase (MTHFR) poly-
morphism. Involved in the methylation of homocysteine,
MTHFR mutations may lead to hyperhomocysteinemia,
which is a risk factor for arterial disease and venous throm-
bosis. However, studies looking at the relationship between
MTHFR mutations and venous thrombosis have been in-
consistent.8,9
During her hospitalization, our patient was diagnosed
with a nonspecific colitis. Patients with inflammatory bowel
disease (IBD) are at increased risk of thromboembolic
events. It is unclear whether the specific inflammatory
bowel disease leads to increased thrombotic events or
whether this is due to chronic inflammation. In one study,
genetic mutations which could increase the risk of throm-
bosis were not found to be different in patients with IBD vs
the normal population.10 Ten percent of patients with
phlegmasia have no apparent risk factors.
There is no consensus for the treatment of PCD. Pa-
tients should first receive treatment with systemic anticoag-
ulation, leg elevation, compression stockings, and fluid
resuscitation.11 Surgical thrombectomy had historically
been the primary therapy for patients who were refractory
to systemic therapy; however, perioperative recurrence and
damage of venous valves often occur. Thrombolytic ther-
apy has evolved from systemic administration to catheter-
directed delivery. Catheter-directed thrombolysis mini-
mizes systemic exposure and has a high success rate but still
exposes the patient to a small (typically less than 1%) risk of
severe hemorrhage.4,12-14
Mechanical adjuncts to thrombolysis include the use of
rotational and hydrodynamic recirculation devices to frag-
ment the thrombus. AngioJet uses hydrodynamic recircu-
lation and relies on the Venturi effect to create a vortex that
pulls in thrombus and causes it to fragment. A separate
exhaust port allows for evacuation of the fragmented
thrombus. The use of balloon venoplasty and stenting has
its role in the treatment of lesions that are not amenable to
further thrombolysis.14 The role of endoluminal venous
stents in adult patients with MTS in short-term follow-up
has been shown to have low morbidity and high patency
rates with low rates of recurrent venous thromboembo-
lism.2,5,14-18 For these reasons, it has been advanced as the
treatment of choice by many authors. However, recom-
mendations for pediatric patients with MTS are scarce. The
size of the pediatric patient and long-term implications of a
permanent intravenous stent need to be carefully consid-
ered before placing stents. In our current patient, the early
partial rethrombosis and anatomic findings of MTS pressed
the need for stenting at the secondary intervention.
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patient has not been previously reported. The authors
present a unique case of a girl with PCD and multiple risk
factors for deep venous thrombosis in whom an aggressive
multimodal approach resulted in limb salvage. The tech-
niques of catheter-directed thombolytic therapy and ve-
nous stenting developed in the adult population can be
successfully translated to the pediatric population.
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